Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Apexbio Technology LLC Z-DEVD-FMK 210344-95-9 25mg
SDP

Catalog No. 5000063122
Encompass_Preferred

Z-DEVD-FMK (CAS 210344-95-9) is a tetrapeptide inhibitor primarily targeting caspase-3 a protease involved in apoptotic neuronal cell death Beyond caspase-3 inhibition Z-DEVD-FMK also directly suppresses calpain-mediated proteolysis notably reducing calpain-induced spectrin degradation In vitro studies confirm Z-DEVD-FMK attenuates necrotic neuronal death independently of caspase-3 activity In vivo following traumatic brain injury (TBI) or cerebral ischemia administration of Z-DEVD-FMK limits lesion size reduces tissue damage and improves functional neurological outcomes likely due to combined inhibition of caspase-3 and calpain pathways

Catalog No. 50-000-63122 Supplier Apexbio Technology LLC Supplier No. A192025
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Z-DEVD-FMK (CAS 210344-95-9) is a tetrapeptide inhibitor primarily targeting caspase-3 a protease involved in apoptotic neuronal cell death Beyond caspase-3 inhibition Z-DEVD-FMK also directly suppresses calpain-mediated proteolysis notably reducing calpain-induced spectrin degradation In vitro studies confirm Z-DEVD-FMK attenuates necrotic neuronal death independently of caspase-3 activity In vivo following traumatic brain injury (TBI) or cerebral ischemia administration of Z-DEVD-FMK limits lesion size reduces tissue damage and improves functional neurological outcomes likely due to combined inhibition of caspase-3 and calpain pathways

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.